Navigation Links
InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
Date:9/12/2011

t IPF patients in the United States.  At this time pirfenidone is not approved for use in the United States.

About IPF

Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating and ultimately fatal disease characterized by inflammation and scarring (fibrosis) in the lungs, hindering the ability to process oxygen.  IPF is a progressive disease, meaning that over time, lung scarring and symptoms increase in severity.  The median survival time from diagnosis is two to five years, with a five-year survival rate of approximately 20-40 percent, which makes IPF more rapidly lethal than many cancers, including breast, ovarian and colorectal.  An estimated 30,000-35,000 new cases of IPF are diagnosed in Europe each year. Patients diagnosed with IPF are primarily between the ages of 40 and 80, with a median age of 63 years.  The disease tends to affect slightly more men than women.  

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune, please visit www.intermune.com.

Forward-Looking Statements


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
2. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
3. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
4. InterMune to Present at J.P. Morgan Healthcare Conference
5. InterMune Reports Third Quarter 2010 Financial Results
6. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
7. InterMune to Release Second Quarter Financial Results on July 27
8. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
9. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
10. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
11. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 /PRNewswire/ ... three-quarters of surveyed infectious disease (ID) specialists are ... Medicines Company,s Orbactiv (oritavancin) for use as OPAT, ... to prescribe these agents to their hospital inpatients. ... percent) of OPAT patients are initiated on OPAT ...
(Date:1/15/2014)... N.Y. , Jan. 15, 2014 Sono-Tek Corporation (OTC ... months ended November 30, 2013, compared to sales of $2,202,000 ... 20%. Once again, this quarter has also shown growth over ... the first quarter of this fiscal year. Markets that experienced ...
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3
... ANNAPOLIS, Md., April 28 /PRNewswire-FirstCall/ -- PharmAthene, ... company developing medical countermeasures against biological and chemical threats, ... call for investors on Wednesday, April 29th beginning at ... rPA anthrax vaccine program. The dial-in number within the ...
... Urological Association Annual Meeting --SEATTLE and CHICAGO, April ... DNDN ) today presented preclinical data demonstrating ... molecule, which targets TRPM8 (a transmembrane cation channel ... D-3263 demonstrated the ability to reduce BPH alone ...
Cached Medicine Technology:PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program 2Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia 2Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia 3Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia 4
(Date:7/12/2014)... 2014 In this cognitive ... assessment and training’ is defined as solution ... or enhance cognitive functions. These solutions are ... dementia screening, clinical trials, driver’s safety, rehabilitation, ... assessment, brain training, and employers’ assessment and ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 The Security ... in 2013 to $3,376.6 million by 2019, at an ... and 2019. The challenges to counter the increasing number ... existence of outdated cyber defense systems in organizations are ... innovating and remodeling their existing architecture to develop better ...
(Date:7/12/2014)... New York (PRWEB) July 12, 2014 ... damage allegations continue to move forward in the ... Eastern District of Pennsylvania, Bernstein Liebhard LLP reports. ... U.S. District Judge Lawrence F. Stengel has ordered ... other things, Judge Stengel found that the witness’s ...
(Date:7/12/2014)... (HealthDay News) -- If you make exercise fun, you,ll eat ... experiment, 56 adults were led on a 1.4-mile walk and ... a scenic walk. The participants were given lunch after the ... outing ate 35 percent more chocolate pudding for dessert than ... In another experiment, 46 adults were given mid-afternoon snacks after ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 "The second toes ... uncomfortable and painful to wear shoes," said an inventor from ... sock that prevents this from happening. , He then created ... way to prevent the second and big toes from overlapping. ... while wearing shoes. Ergonomic and easy to use, it's ideal ...
Breaking Medicine News(10 mins):Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Make Exercise Fun, Eat Less Afterwards 2
... you think. Low doses of radiation have been found to ... not uncommon for children who suffer from medulloblastoma to undergo ... in affecting IQ and reading skills of younger children rather ... has been found that the greatest rates of decline in ...
... has claimed at least 20 lives in the past two ... is already present in the neighboring Indian state of UP ... caused 10 deaths each in the townships of Tikapur and ... over 80 patients were undergoing treatment in various hospitals and ...
... that the loss of a gene called p63 accelerates the ... present in many organisms, including humans // . Drawing parallels ... is likely to play a fundamental biological role in aging-related ... researchers had devised a system for eliminating it from adult ...
... prevent infections in older people living at home, report ... segment of the supplement-taking population. //, ,Studies in ... supplements, elderly people in nursing homes were 20 per ... had fewer colds over the study period than a ...
... at Jefferson Medical College had discovered the existence of ... biomarker for conditions that lead to heart failures. Based ... a blood test to predict the onset of heart ... previously showed that an enzyme called GRK2 or beta-adrenergic ...
... become nearly twice as prevalent in high schools in the ... middle school students admit that drugs are used, kept or ... where drugs are widely available are three times more likely ... alcohol than their peers who attend drug-free schools., ,Availability ...
Cached Medicine News:Health News:Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly 2Health News:Blood Test To Predict Heart Failures 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: